A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35year old men with severe haemophilia in four European countries

Haemophilia

Volumn 17, Issue 5, 2011, Pages

  Noone, D ^a   O'Mahony, B ^a   Prihodova, L ^b  

^a IRISH HAEMOPHILIA SOCIETY   (Ireland)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

BLEEDING; DISEASE SEVERITY; EUROPE; FRANCE; HEMOPHILIA; HUMAN; IRELAND; JOINT PROSTHESIS; LETTER; MALE; ORTHOPEDIC SURGERY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SWEDEN; UNITED KINGDOM;

ABSENTEEISM; ADULT; BLOOD COAGULATION FACTORS; DRUG THERAPY, COMBINATION; FRANCE; GREAT BRITAIN; HEMOPHILIA A; HUMANS; IRELAND; MALE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; SWEDEN; YOUNG ADULT;

EID: 80052038575     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02582.x     Document Type: Letter

References (10)

1. Medical and Scientific Advisory Council (MASAC). MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) on April 22, 2006, and adopted by the NHF Board of Directors on June 3, 2006.
2. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders - A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline - Approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
3. Ludlam CA, Mannucci PM, Powderly WG. Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. Haemophilia 2005; 11: 433-7.
4. Van den Berg HM, Fischer K, Van der Bom JG. Comparing outcomes of different treatment regimens for severe haemophilia. Haemophilia 2003; 9: 27-31.
5. Petrini P, Chambost H, Nemes L. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia 2004; 10: 94-6.
6. Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia 2007; 13: 4-9.
7. Carcao M, Chambost H, Ljung R. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia 2010; 16: 4-9.
8. Lippert B, Berger K, Berntorp E et al. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagul Fibrinolysis 2005; 16: 477-85.
9. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Haemophilia 2008; 14: 743-52.
10. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.